CC BY-NC-ND 4.0 · Revista Urología Colombiana / Colombian Urology Journal 2018; 27(01): 110-114
DOI: 10.1016/j.uroco.2017.03.006
Original Article | Artículo Original
Sociedad Colombiana de Urología. Publicado por Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Comparison of the excretory capacities of erythropoietin and U-74389G concerning serum creatinine levels

Comparación de las capacidades excretoras de eritropoyetina y U-74389G respecto a los niveles de creatinina sérica
Constantinos Tsompos
1   Consultant A, Department of Obstetrics & Gynecology, Mesologi County Hospital, Etoloakarnania, Greece
,
Constantinos Panoulis
2   Assistant Professor, Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Attiki, Greece
,
Konstantinos Toutouzas
3   Assistant Professor, Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki, Greece
,
Aggeliki Triantafyllou
4   Associate Professor, Department of Biologic Chemistry, Athens University, Attiki, Greece
,
George Zografos
5   Professor, Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki, Greece
,
Apostolos Papalois
6   Director, Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Attiki, Greece
› Author Affiliations
Further Information

Publication History

29 December 2016

13 March 2017

Publication Date:
10 January 2018 (online)

Abstract

Introduction This study compared the excretory effects, the erythropoietin (Epo) and antioxidant drug U-74389G exert on serum creatinine levels through kidneys. 2 preliminary studies were used for this purpose including respectively one drug used in a renal ischemia–reperfusion (IR) protocol of an animal model. The preliminary studies are part of the present work. The subjects were pretreated in preliminary studies but the results of the same subjects were simply compared in the current work.

Materials and methods The serum creatinine levels were evaluated at the 60th reperfusion min (for groups A, C and E) and at the 120th reperfusion min (for groups B, D and F) after IR in the 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo, whereas rats from groups E and F were administered with U-74389G.

Results The first preliminary study recommended a non-significant excretory effect of Epo (p-value = 0.4430 > 0.05) than placebo for serum creatinine levels. The second preliminary study proved a very significant excretory effect of U-74389G (p-value = 0.0005 < 0.05) than placebo for serum creatinine levels. These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has at least 5-fold significant excretory action (p-value = 0.0000 < 0.05) than Epo for serum creatinine levels.

Conclusions The U-74389G presents surprising effective excretory potencies for serum creatinine levels maybe of great importance in hemodialysis patients.

Resumen

Introducción Este estudio comparó los efectos excretores que la eritropoyetina (Epo) y el fármaco antioxidante U-74389G ejercen sobre los niveles de creatinina sérica a través de los riñones. Se utilizaron 2 estudios preliminares incluyendo, respectivamente, un fármaco utilizado en una rata protocolo de reperfusión de isquemia renal. Los estudios preliminares son parte del presente trabajo. Los sujetos fueron pretratados en estudios preliminares, pero los resultados de los mismos sujetos fueron comparados simplemente en el trabajo actual.

Materiales y métodos Se evaluaron los niveles de creatinina sérica en la 60.ª reperfusión en minutos (para los grupos A, C y E) y en la 120.ª reperfusión en minutos (para los grupos B, D y F) después de isquemia renal en las 60 ratas. Los grupos A y B no recibieron fármacos, a las ratas de los grupos C y D se les administró Epo, mientras que las ratas de los grupos E y F se les administró U-74389G.

Resultados El primer estudio preliminar recomendó un efecto excretor no significativo de la Epo (valor p = 0,4430 > 0,05) comparado con el placebo para los niveles de creatinina sérica. El segundo estudio preliminar demostró un efecto excretor muy significativo del U-74389G (valor p = 0,0005 < 0,05) comparado con el placebo para los niveles de creatinina sérica. Estos 2 estudios fueron coevaluados, ya que procedían del mismo entorno experimental. El resultado fue que el U-74389G tiene una acción excretora significativa de al menos 5 veces (p = 0,0000 < 0,05) la Epo para los niveles de creatinina sérica.

Conclusiones El U-74389G presenta sorprendentes potencias excretoras efectivas para los niveles de creatinina sérica, tal vez de gran importancia en pacientes en hemodiálisis.

 
  • References

  • 1 Τsompos C, Panoulis C, Τoutouzas K, Ζografos G, Papalois A. The effect of the antioxidant drug U-74389G on creatinine levels during ischemia reperfusion injury in rats. Curr Urol 2015; 9: 73-78
  • 2 Tsompos C, Panoulis C, Toutouzas K, Zografos G, Papalois A. The effect of erythropoietin on creatinine levels during ischemia reperfusion injury in rats. Literati J Pharm Drug Deliv Technol 2015; 1: 1-6
  • 3 Elshiekh M, Kadkhodaee M, Seifi B, Ranjbaran M, Ahghari P. Ameliorative effect of recombinant human erythropoietin and ischemic preconditioning on renal ischemia reperfusion injury in rats. Nephrourol Mon 2015; 7: e31152
  • 4 Cakiroglu F, Enders-Comberg SM, Pagel H, Rohwedel J, Lehnert H, Kramer J. Erythropoietin-enhanced endothelial progenitor cell recruitment in peripheral blood and renal vessels during experimental acute kidney injury in rats. Cell Biol Int 2016; 40: 298-307
  • 5 Kalantzi M, Kalliakmani P, Papachristou E, Papasotiriou M, Savvidaki E, Zavvos V. , et al. Parameters influencing blood erythropoietin levels of renal transplant recipients during the early post-transplantation period. Transplant Proc 2014; 46: 3179-3182
  • 6 Hernández-Navarrete LS, Hernández-Jiménez JD, Jiménez-López LA, Budar-Fernández LF, Méndez-López MT, Martínez-Mier G. Experience in kidney transplantation without blood transfusion: kidney transplantation transfusion-free in Jehovah's Witnesses. First communication in Mexico. Cir Cir 2013; 81: 450-453
  • 7 Gardner DS, Welham SJ, Dunford LJ, McCulloch TA, Hodi Z, Sleeman P. , et al. Remote conditioning or erythropoietin before surgery primes kidneys to clear ischemia–reperfusion-damaged cells: a renoprotective mechanism?. Am J Physiology Renal Physiology 2014; 306: F873-F884
  • 8 Ahmadiasl N, Banaei S, Alihemmati A, Baradaran B, Azimian E. The anti-inflammatory effect of erythropoietin and melatonin on renal ischemia reperfusion injury in male rats. Adv Pharm Bull 2014; 4: 49-54
  • 9 Wu Y, Zhang J, Liu F, Yang C, Zhang Y, Liu A. , et al. Protective effects of HBSP on ischemia reperfusion and cyclosporine a induced renal injury. Clin Dev Immunol 2013; 2013: 758159
  • 10 Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL. Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care 2013; 17: R254
  • 11 Li XJ, Zhang GX, Sun N, Sun Y, Yang LZ, Du YJ. Protective effects of erythropoietin on endotoxin-related organ injury in rats. J Huazhong Univ Sci Technol Med Sci 2013; 33: 680-686
  • 12 Moeini M, Nematbakhsh M, Fazilati M, Talebi A, Pilehvarian AA, Azarkish F. , et al. Protective role of recombinant human erythropoietin in kidney and lung injury following renal bilateral ischemia–reperfusion in rat model. Int J Prev Med 2013; 4: 648-655
  • 13 Han X, Zhao L, Lu G, Ge J, Zhao Y, Zu S. , et al. Improving outcomes of acute kidney injury using mouse renal progenitor cells alone or in combination with erythropoietin or suramin. Stem Cell Res Ther 2013; 4: 74
  • 14 Matějková Š, Scheuerle A, Wagner F, McCook O, Matallo J, Gröger M. , et al. Carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine kidney ischemia/reperfusion injury. Intensive Care Med 2013; 39: 497-510
  • 15 Ardalan MR, Estakhri R, Hajipour B, Ansarin K, Asl NA, Nasirizade MR. , et al. Erythropoietin ameliorates oxidative stress and tissue injury following renal ischemia/reperfusion in rat kidney and lung. Med Princ Pract 2013; 22: 70-74
  • 16 Ulusoy S, Ozkan G, Menteşe A, Yavuz A, Karahan SC, Sümer AU. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level. Clin Biochem 2012; 45: 1444-1449
  • 17 Imamura R, Isaka Y, Sandoval RM, Ichimaru N, Abe T, Okumi M. , et al. A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney. Clin Exp Nephrol 2012; 16: 852-862
  • 18 Rodrigues CE, Sanches TR, Volpini RA, Shimizu MH, Kuriki PS, Camara NO. , et al. Effects of continuous erythropoietin receptor activator in sepsis-induced acute kidney injury and multi-organ dysfunction. PLoS ONE 2012; 7: e29893
  • 19 Oba S, Suzuki E, Nishimatsu H, Kumano S, Hosoda C, Homma Y. , et al. Renoprotective effect of erythropoietin in ischemia/reperfusion injury: possible roles of the Akt/endothelial nitric oxide synthase-dependent pathway. Int J Urol 2012; 19: 248-255
  • 20 Hu L, Yang C, Zhao T, Xu M, Tang Q, Yang B. , et al. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. J Surg Res 2012; 176: 260-266
  • 21 Chrysikos DT, Sergentanis TN, Zagouri F, Psaltopoulou T, Theodoropoulos G, Flessas I. , et al. Lazaroid U-74389G administration in pancreatic ischemia–reperfusion injury: a swine model encompassing ischemic preconditioning. JOP 2015; 16: 176-184
  • 22 Tsompos C, Panoulis C, Toutouzas K, Zografos G, Papalois A. Comparison of the acute erythropoietic capacities of erythropoietin and U-74389G concerning hemoglobin levels. Blood Res 2017; [in press]